Page 3 - மின்னணு ஆவணம் சேகரித்தல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மின்னணு ஆவணம் சேகரித்தல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மின்னணு ஆவணம் சேகரித்தல் Today - Breaking & Trending Today

Aurinia Pharmaceuticals Inc.: Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

Aurinia Pharmaceuticals Inc.: Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH TSX:AUP) ( Aurinia or the Company ) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine. ....

United States , United Kingdom , Makoto Inoue , Stefan Riley , Glenn Schulman , Peter Greenleaf , Dana Lynch , Aurinia Pharmaceuticals Inc , Exchange Commission Electronic Document Gathering , Drug Administration , Otsuka Pharmaceutical Company , Corporate Communications , European Union , European Medicines Agency , Pharmaceuticals Medical Devices Agency , Otsuka Pharmaceutical Co Ltd , Aurinia Pharmaceuticals , Otsuka Holdings Co Ltd , Lupus Nephritis , Prescription Drug User Fee Act , Chief Executive Officer , Representative Director , British Columbia , Looking Statements , Annual Information Form , Canadian Securities Administrator System ,

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments – – Agreement includes royalties of up to 20 percent on net sales payable to Aurinia – Aurinia Pharmaceuticals Inc. today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral …
– Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments – ....

United States , United Kingdom , Makoto Inoue , Stefan Riley , Glenn Schulman , Peter Greenleaf , Dana Lynch , Aurinia Pharmaceuticals Inc , Exchange Commission Electronic Document Gathering , Drug Administration , Otsuka Pharmaceutical Company , Corporate Communications , European Union , European Medicines Agency , Pharmaceuticals Medical Devices Agency , Otsuka Pharmaceutical Co Ltd , Aurinia Pharmaceuticals , Otsuka Holdings Co Ltd , Lupus Nephritis , Prescription Drug User Fee Act , Chief Executive Officer , Representative Director , British Columbia , Annual Information Form , Canadian Securities Administrator System , Electronic Document Analysis ,

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
businesswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businesswire.com Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Switzerland General , Peter Greenleaf , Facebook Lonzagroup , Gordon Bates , Lonza Group Ltd , Aurinia Pharmaceuticals Inc , Exchange Commission Electronic Document Gathering , Drug Administration , Swiss Exchange , Lonza Ltd , Small Molecules Division , Aurinia Pharmaceuticals , Singapore Exchange Securities Trading Limited , Chief Executive Officer , President Small Molecules Division , Priority Review , Prescription Drug User Fee Act , Fast Track , British Columbia , Swiss Alps , Annual Information Form , Canadian Securities Administrator System , Electronic Document Analysis , Exchange Commission ,